5 big analyst AI moves: Apple lifted to Buy, AI chip bets reassessed
Director Bruce Booth indirectly sold shares of Sionna Therapeutics, Inc. (NASDAQ:SION) on October 21, 2025, in a series of transactions totaling $3.04 million. The sales were executed at prices ranging from $32.69 to $36.42. The stock has shown remarkable strength, gaining over 180% in the past six months, with InvestingPro data showing the current price of $42.50 trading near its 52-week high.
The sales were conducted in multiple transactions through two entities: Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P.
Through Atlas Venture Fund XI, L.P., a total of 73,458 shares were sold. These sales were executed in multiple tranches at weighted average prices of $32.69, $33.87, $34.91, $35.69 and $36.42.
Through Atlas Venture Opportunity Fund II, L.P., a total of 15,311 shares were sold. These sales were executed in multiple tranches at weighted average prices of $32.69, $33.87, $34.91, $35.69 and $36.42.
These transactions were made pursuant to a Rule 10b5-1 trading plan. Following these transactions, Atlas Venture Fund XI, L.P. holds 2,309,035 shares and Atlas Venture Opportunity Fund II, L.P. holds 686,567 shares of Sionna Therapeutics , Inc.
In other recent news, Sionna Therapeutics announced the initiation of its PreciSION CF Phase 2a trial, evaluating SION-719 in combination with standard cystic fibrosis treatment, Trikafta. This marks the first clinical evaluation of an NBD1 stabilizer in cystic fibrosis patients. Additionally, the company has started a Phase 1 trial testing novel cystic fibrosis treatment combinations, including SION-451 with SION-2222 and SION-109, to assess safety and pharmacokinetics in healthy volunteers.
On the financial front, Guggenheim reiterated its Buy rating on Sionna Therapeutics with a $45 price target, following positive Phase I safety and pharmacokinetic data. Freedom Capital Markets also initiated coverage on Sionna Therapeutics with a Buy rating and a $38 price target. Meanwhile, RBC Capital initiated coverage with a Sector Perform rating and a $22 price target. These developments highlight the growing interest in Sionna’s innovative approach to cystic fibrosis treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.